

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6639051

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
JOHN BAXTER BIGGINS	09/17/2020
BRIAN ROGER BOWMAN	09/16/2020
GREGORY L. VERDINE	09/17/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	LIFEMINE THERAPEUTICS, INC.
<b>Street Address:</b>	30 ACORN PARK DRIVE
<b>City:</b>	CAMBRIDGE
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02140
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16646978
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	patentdocket@choate.com
<b>Correspondent Name:</b>	CHOATE, HALL AND STEWART LLP
<b>Address Line 1:</b>	TWO INTERNATIONAL PLACE
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	2012710-0009
<b>NAME OF SUBMITTER:</b>	XIAODONG LI
<b>SIGNATURE:</b>	/Xiaodong Li/
<b>DATE SIGNED:</b>	04/05/2021
<b>Total Attachments: 8</b>	
source=2012710_0009_Assignment#page1.tif	
source=2012710_0009_Assignment#page2.tif	
source=2012710_0009_Assignment#page3.tif	
source=2012710_0009_Assignment#page4.tif	
source=2012710_0009_Assignment#page5.tif	

source=2012710\_0009\_Assignment#page6.tif

source=2012710\_0009\_Assignment#page7.tif

source=2012710\_0009\_Assignment#page8.tif

**COMBINED JOINT ASSIGNMENT & DECLARATION****A. ASSIGNMENT**

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

<b>Inventor Name</b>	<b>City, State</b>
<b>1. John Baxter Biggins</b>	Long Beach, New York
<b>2. Brian Roger Bowman</b>	New Rochelle, New York
<b>3. Gregory L. Verdine</b>	Boston, Massachusetts

Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

**HUMAN THERAPEUTIC TARGETS AND MODULATORS THEREOF; and**

☐ prepared for filing in the United States Patent and Trademark Office; or

☒ identified by United States Application No. 16/646,978  
filed in the United States Patent and Trademark Office on March 12, 2020; and

☒ identified by International Patent Application No. PCT/US18/51134  
filed on September 14, 2018; and

☒ and is also aware of the following priority applications:

<b>Application No.</b>	<b>Filed</b>
<u>62/558,744</u>	<u>September 14, 2017</u>

WHEREAS, **LIFEMINE THERAPEUTICS, INC.** (hereinafter "ASSIGNEE"), having a usual place of business at **30 Acorn Park Drive, Cambridge, Massachusetts 02140**, desires to acquire or confirm an interest therein;

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, each of us hereby confirms, agrees, and/or declares that:

1. I have sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and

interest in and throughout the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application;

2. My sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by me had this sale, assignment and transfer not been made;

3. This Assignment, being of my entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;

4. I, or my executor(s) and/or administrator(s) will execute upon request any other lawful documents and likewise will perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts I know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;

5. I hereby authorize ASSIGNEE or its attorneys or agents to insert the correct application number(s) and/or filing date(s) into this assignment document, if appropriate;

6. I hereby appoint ASSIGNEE as my common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

7. I hereby request the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;

8. I hereby covenant with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by me, and that full right to convey the same as herein expressed is possessed by me.

**B. DECLARATION (37 CFR 1.63)**

As a below named inventor, I hereby declare that:

This declaration is directed to the patent application entitled:

**HUMAN THERAPEUTIC TARGETS AND MODULATORS THEREOF; and**

☐ attached hereto or prepared for filing in the United States Patent and Trademark Office; or

☐ identified by United States Application No. \_\_\_\_\_  
filed in the United States Patent and Trademark Office on \_\_\_\_\_; or

☒ identified by International Patent Application No. PCT/US18/51134  
filed on September 14, 2018.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

I have reviewed and understand the contents of the application, including the claims and am aware of the duty to disclose to the United States Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR 1.56.

Signature:

John Baxter Higgins

Date:

9/17/2020

Witness Signature:

Bennie Dempsey

Witness Name (printed):

Bennie Dempsey

Witness Signature:

Joan Ryan

Witness Name (printed):

Joan Ryan

Signature: Brian Bowman  
Brian Roger Bowman

Date: 9/16/20


Witness Signature: Teresa Bowman

Witness Name (printed): Teresa Bowman


Witness Signature: Leonard W. Hooper

Witness Name (printed): LEONARD W. HOOPER



Signature:   
Gregory L. Verdine


Date: 9-17-2020

Witness Signature:   
Witness Name (printed): Lauren Lopez

Witness Signature:   
Witness Name (printed): Rachel Wallace

The ASSIGNEE hereby acknowledges and accepts the foregoing assignment.

The undersigned (whose title is supplied below) is authorized to act on behalf of the ASSIGNEE.

Signature:  Date: 9-17-2020

Name (printed): Gregory L. Verdine

Title (printed): President and CEO